Skip to content
Back

Combined respiratory epithelial cell and gene therapy for amelioration of respiratory symptoms in children with junctional epidermolysis bullosa (Butler 1)

Ongoing
Project lead Dr Colin Butler
Organisation UCL Great Ormond Street Institute of Child Health, London, UK
Partner organizations & collaborators Co applicants: Professor Sam Janes, Head of Respiratory Research Department at UCL, Professor Paolo De Coppi, Neonatal specialist at UCL
In conjunction with: Dr Gabriela Petrof, Dr Anna Martinez, Mr Richard Hewitt (Paediatric Otolaryngologist Ear Nose and Throat GOSH)
Project budget GBP 135,337.56
Start date / Duration 01. Jan 2021 / 24 months
Funder(s) / Co-Funder(s) DEBRA UK, DEBRA Austria, MSAP/EBEP Recommended
Research area Skin cancer & fibrosis, Symptom prevention & relief

Project details

Short lay summary

Epidermolysis bullosa (EB) is a genetic disorder where patients suffer from extremely fragile surface tissues which painfully blister and scar with minimal trauma. It predominantly affects the external skin, however, the voicebox and windpipe can also be significantly affected. Treatment options for airway EB are very limited and often affected individuals will have difficulty swallowing and can suffer worsening breathing difficulties from airway scarring. Eventual airway blockage creates the need for a tracheostomy, a medical procedure to help open the airway. The research in this area has identified that skin grafts in the airway may provide the possibility of delivering gene-corrected airway cells to help provide a potential cure for airway disease in EB.

The gene that will be focussed on in this project is the LAMA3 gene, which is responsible for the laminin protein. This protein is important for helping cells attach to one another to provide strength to the skin and other tissues found in the airways, as well as being involved in the process of wound healing. The work here aims to discover whether a gene based therapy may help with correcting the lining of the airway that is affected by EB. Cells will be used from the airway and the LAMA gene then corrected outside of the body and reintroduced to see whether this technique will work to stop airway disease. 

Scientific summary

The effects of epidermolysis bullosa (EB) in the airway are heterogenous and the full extent of airway involvement remains unknown. In patients that suffer significant morbidity and mortality as a result of epithelial disease in the larynx and trachea, the most common mutation is in the LAMA3 gene, encoding the alpha3 chain of the laminin protein. Leveraging advances in the ability to expand airway epithelial stem/progenitor cells, this proposal aims to better characterise the airway epithelium from patients with airway EB and to develop autologous LAMA3 gene-edited airway epithelial cells as a potential curative approach.

Strategic relevance

This research may also open the possibility to correct forms of EB that also affect other tissues in the body, including corneal (eye) epithelium and mucous membranes of the aerodigestive tract, (nose, lips, mouth, tongue, throat, vocal chords and upper part of the oesophagus and windpipe).

The ability to generate cell lines for airway disease in EB using this technique will also open the prospect of personalised drug testing for mass screening of small molecular compounds. This means finding a specific treatment for an individual using the data collected from this research.

More on DEBRA UK's website


Keywords

Junctional EB
airway fibrosis
gene therapy
Butler
UCL
respiratory
Back to main navigation